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Abstract
Modern high-throughput molecular technologies (collectively referred to as “omic”
platforms) are generating unprecedented amounts of data on human variation. The four
papers in this thesis each investigate and characterize associations between common,
complex, heritable disease, and genetic or metabolomic markers from omic platforms.
In paper I, we searched bipolar affective disorder (BPAD) pedigrees for genomic
copy-number variants (CNVs, segmental deletions or duplications) segregating with
disease. In one pedigree, a deletion in the gene MAGI1 was observed in six out of six
affected members. Upon further inspection, another pedigree was found with two out of
three affected members carrying a duplication in the same gene. A pooled association
analysis was subsequently carried out using in-house and public data sets on CNVs
in control subjects and cases of BPAD, schizophrenia (SZ), or schizoaffective disorder
(SA). MAGI1 CNVs greater than 100 kb were found to be rare, nonsignificantly more
common in BPAD cases than in controls, and significantly more common in the pooled
case sample of BPAD, SZ, and SA than in controls.
In paper II, we studied a rare single nucleotide polymorphism (SNP) in the gene
HOXB13, which had been recently reported to be strongly associated with prostate
cancer (PC) risk. We genotyped and analyzed the variant G84E (rs138213197) in the
two large Swedish PC case-control samples CAPS and Stockholm-1 (in total 4,903 cases
and 4,589 controls). G84E was less rare in the Swedish samples than in the United
States population previously studied, with a carrier rate over 1% in Swedish population
controls. The variant was associated with a more than threefold increased relative risk
of PC in both Swedish samples. G84E carriers’ absolute lifetime risk to age 80 of PC
was estimated to 33%. For G84E carriers in the uppermost quartile of a genetic risk
score based on common risk SNPs, the same lifetime risk was estimated to 48%.
In paper III, a replication study of previously reported genetic associations with
testicular germ cell tumor (TGCT) risk was performed. SNPs in six genes (ATF7IP,
BAK1, DMRT1, KITLG, SPRY4, and TERT ) were genotyped and analyzed in a
combined case-parent, case-control sample from Sweden and Norway. In total, 831
case-parent triads, 474 dyads, 712 singleton cases, and 3,919 control subjects were
analyzed. Our results supported the previously reported association with TGCT risk
for SNPs in all six genes. Tests of interaction effects revealed no allelic effect differences
for the two major TGCT histological subtypes seminoma and non-seminoma. However,
a variant in the gene SPRY4 was found to differ significantly in effect depending on
the sex of the parent from which it was inherited. Only maternally inherited alleles
were associated with TGCT risk.
In paper IV, a large range of small molecules in human serum, collectively called the
metabolome, were studied for association with PC risk and aggressiveness. Samples from
188 controls, 188 PC patients with indolent disease, and 99 PC patients with aggressive
disease were analyzed by ultra-performance liquid chromatography coupled with mass
spectrometry, generating 6,138 quantitative molecular features. All features were tested
for association with PC status, adjusted for patient age and sample storage time. Two
features were significantly associated after correction for multiple testing, but none of
them could be identified as specific molecules. Testing the PC-associated features for
association with 1.4 million SNPs genome-wide produced the strongest associations in
variants in annotated genes, which may aid future molecular identification efforts.
In conclusion, we have used omics platforms and modern computational tools to
increase our knowledge about specific genetic risk factors and metabolomic markers for
complex heritable disease. Our results may come of use in future etiological research as
well as in genetic and molecular risk assessment.
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1 Introduction
This thesis is composed of four studies of genetic variation associated with human disease
(papers I–III), or with metabolomic traits that are in turn associated with disease (paper
IV). The first section briefly introduces key concepts of molecular biology, genetics and
epidemiology upon which these studies rest, followed by a description of the heritable human
diseases studied herein.
1.1 The central dogma of molecular biology
Modern molecular biology began with the discovery of the molecular structure of deoxyri-
bonucleic acid (DNA) in 1953 [1], suggesting a mechanism for its accurate self-replication,
and that the sequence of bases constituting this long, fibrous molecule may be the code that
holds genetic information [2]. The hypotheses proved to hold, and since then, the molecule
has been studied in relation to countless traits and diseases.
The central dogma of molecular biology (as most often described) states that information
mainly flows in one direction, from DNA, through ribonucleic acid (RNA), ending up in
a protein (Figure 1). This is a straightforward path from information (DNA) to function
(proteins), comparable to that of a simple computer program, where information in human-
readable source code format is translated by a compiler to machine code, which instructs the
processor to act on data.
1.2 It’s complicated
Unfortunately (to simple-minded life scientists), life is not as simple as pictured in the “central
dogma”, and this has been known for as long as the dogma has existed. In fact, the dogma
DNA RNA Protein
Transcription Translation
Replication
Figure 1 – The central dogma of molecular biology, as often described.
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was originally stated in a negative fashion, and held that information flow from protein to
DNA, from protein to RNA, and from protein to protein is unlikely to occur (Figure 2, [3]).
While the simplified principle of “DNA to RNA to protein” is true in general, it covers far
from every process in the cells of even prokaryotes (bacteria), and even less of what happens
in eukaryotes (plants and animals). For example, DNA is not only a linear information carrier,
but has complex structure, and is modified by epigenetic events such as methylation [4].
RNA, besides being an agent for information transfer from nuclear DNA to protein
(messenger RNA, mRNA) also takes on tertiary structure to catalyze processes in the cell
(ribosomal RNA, rRNA, form most of the ribosomes, which translate mRNA to protein),
while small interfering RNA (siRNA) acts on complementary DNA sequences to silence
specific genes [5]. Finally, long intergenic non-coding RNA (lincRNA) has been shown to take
part in gene regulation and modification of the histone structure of DNA [6], and specific
lincRNAs have been linked to cancer, both as tumor suppressors and as oncogenes [7].
If we not only consider information transfer, but any molecular interaction in the cell,
such as enzymes acting on small and large molecules in the metabolome, proteins acting as
structural support for DNA packing, et cetera, the picture becomes even more complicated,
and starts approaching real life.
Returning to the computer program analogy then, real life is more like a large body of mas-
sively parallel, constantly interacting, self-modifying spaghetti code than the straightforward
process suggested by the simplicity of the central dogma in its simplified form.
Nevertheless, even a vastly simplified model can be useful in making inferences and
increasing understanding of the great puzzle of life piece by piece.
1.3 Classes of genetic variation
Early genetic studies used directly observable traits as indicators of which alleles had been
inherited. Gregor Mendel studied, among other traits, the shape (wrinkled or smooth) and
color of different varieties of peas, and especially the outcome when crossing two varieties. He
used the terms dominant, for the traits that would always carry over to the hybrid offspring
even from a single parent variety, and recessive, for the traits that needed to be present
(possibly latent) in both parent varieties to show in the offspring [8].
In humans, early studies focused on linkage of traits to markers such as blood groups
and sex, which could be easily observed and followed Mendelian inheritance rules (results
included the sex-linked characters of hemophilia and red-green color blindness) [9].
After the role of DNA as the inheritance molecule and its structure was discovered, and
further technical and biochemical developments, new classes of variation that could be used
as genetic markers started to appear. Restriction fragment length polymorphisms (RFLPs),
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Figure 2 – The central dogma of molecular biology, as originally stated (adapted from [3]), and
closer to the reality of the cell. The solid arrows indicate the general transfers, present in almost
every living cell. The dashed arrows represent special transfers, which are less common and
may require special conditions. Reverse transcription (RNA to DNA) is performed by reverse
transcriptases in retroviruses, and in the extension of telomeres, the repetitive end regions
of chromosomes. RNA replication (RNA to RNA) is performed by some RNA viruses, using
special RNA replicase enzymes. Finally, the dotted arrows represent unknown transfers, which
are unlikely to occur. In addition to the transfers from protein, I have included direct DNA
to protein translation in this category because it has only been detected in special artificial
settings [3].
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variable number tandem repeats (VNTRs) and other similar polymorphisms were discovered
and added to the map of the human genome, and pairwise linkage analysis of markers was
used to organize them in “linkage groups”, corresponding to the physical chromosomes [10]. As
more and more actual genomic sequence became available, the single nucleotide polymorphism
(SNP) class of mutations was found to be widespread in the genome. Although each marker
provides little information, since they only have two alleles, compared to RFLPs and VNTRs
which can have many, the relative abundance of SNP markers was shown to be able to
compensate for the lower information content per marker. By using about three times
as many markers, a biallelic SNP map of 750–1,000 markers was shown to be equivalent
to the microsatellite maps of ∼300–400 markers used at the time for genome screens for
linkage [11]. Today more than 50 million SNP variants are known and organized in the
database dbSNP [12], where each SNP has an identifier on the form “rs”, followed by a string
of digits.
Even more recently, the discovery of abundant polymorphic copy-number variants (CNVs)
in the human genome added another class to the list of human genetic variation [13]. CNVs are
segments of the genome that have been deleted or duplicated, for example by mis-alignment
of homologous chromosomes in meiosis.
1.4 Recombination
Every time a germ cell (sperm or egg) is created by cell division (meiosis), each pair of
paternal and maternal homologous chromosomes recombine (cross over) at least once. This
means that the germ cell chromosomes will consist of DNA sequence segments from both the
paternal and the maternal homologs in the parent cell. This mechanism is the basis for both
linkage and association analyses [10].
1.5 Mapping disease genes in families – genetic linkage analysis
Genetic linkage analysis is a study design which uses family data to map traits to genetic
markers. The underlying hypothesis is that traits may be linked to genetic markers, meaning
the trait is influenced by genetic variation a short (genetic) distance from the marker.
If a trait and a marker are linked, they tend to co-segregate in pedigrees. The amount
of co-segregation under varying degrees of linkage can be modeled, and the model that fits
observations the best can be estimated by maximum likelihood methods. The hypothesis of
linkage versus no linkage can then be tested between a trait and genetic markers genome-wide
to find the most likely linked marker (if any) [10].
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1.6 Humanity as one big family – genetic association analysis
Large human populations share common ancestors if the pedigree is followed far enough back
in time. Due to population history and the process of recombination, genetic markers that
are physically close on a chromosome tend to be inherited together over long stretches of
time. This is one of the mechanisms leading to linkage disequilibrium (LD), which is defined
as a non-zero correlation between the observed alleles of two markers in a population. If a
dense genomic marker map is available, and a disease-causing mutation exists somewhere
in the genome, then there is a high likelihood that some of the markers will be in LD with
the disease mutation, and thus correlated with disease. This is the basic concept of genetic
association analysis, a study design which has dominated the field of human genetics for the
past few years.
An influential paper from 1996 by Risch and Merikangas showed that for common, complex
traits, where individual allelic effect sizes were expected to be modest, association studies
have much better power to detect these effects than linkage analyses of comparable size.
They noted that although a dense genome-wide map of SNP markers for such analysis was
not currently available, this was merely a technical challenge, which would be solved over
time [14]. They also suggested a genome-wide significance threshold of 5× 10−8 to control
the type I error (false positive) rate for the 1,000,000 independent tests they expected to
be required for a comprehensive genome-wide association scan. This threshold is still often
applied in GWAS studies of today.
An early success story of the GWAS era was a study of age-related macular degeneration
(AMD). In what today would be considered a very modestly sized sample of 96 cases and 50
controls, genotyping and analysis of ∼100,000 SNPs uncovered an intronic variant strongly
associated with disease, and in LD with a coding, possibly causal SNP [15]. The first large
(one could say massive) GWAS of common complex disease, using high density SNP chips,
was published by the Wellcome Trust Case-Control Consortium (WTCCC) in 2007. In
the WTCCC study, about 2,000 cases each for seven common diseases were genotyped and
compared to 3,000 shared controls. 24 new risk loci were reported, but with much more
modest effect sizes than those seen for AMD [16]. Today, five years later, thousands of robustly
trait-associated loci have been reported from the combined effort of GWAS studies [17].
1.7 Maps of the human genome – physical and genetic distance
A number of different coordinate systems are in use for describing locations of genes and other
features of the human genome. The chromosome number is common to all these systems,
and is simply based on sorting the 22 pairs of autosomal chromosomes by size (see figure 3),
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Figure 3 – Human male karyotype. Image courtesy of the National Human Genome Research
Institute [18].
with chromosome 1 being the largest, and a special case for the sex chromosomes X and Y,
sometimes referred to as chromosomes 23 and 24.
The most coarse of the physical coordinate systems defines genomic landmarks on the form
{chr}{p/q}{band}, e.g. 8q24. The first part of the landmark identifier is the chromosome
number. The next part of the identifier refers to the centromere, which is a specific region
on each chromosome where it attaches to its sister chromosome during cell division. The
centromere is not, despite its name, centered, but divides chromosomes into their short (petit)
p arm, and the longer q arm. Thus p or q places a landmark on one of two chromosome arms.
Finally, the number after the p or q identifies regions by chromosomal bands, which can be
seen when stained chromosomes are examined by microscope (some bands visible in figure 3).
The bands are numbered starting at the centromere and moving out along each arm. Thus,
8q24 indicates a region by the 24th band on the long arm of chromosome 8 [10].
Genetic distance, in contrast to physical distance on the DNA molecule, stems from the
expected rate of recombination between two markers on the chromosome. Genetic distance is
measured in centiMorgans (cM), and is defined such that the expected number of crossovers
(where the germ cell’s sequence switches from maternal to paternal or vice versa) in one
generation between two markers that are 1 cM apart is 0.01. Genetic distance is not uniform
across the physical chromosome, and furthermore differs between sexes, with the female map
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being longer due to a higher number of average crossovers in the production of egg cells. The
length of the genetic map has been estimated to 27 Morgans in males and 39 Morgans in
females [10].
Since the (almost) complete human reference sequence of approximately 3 billion base
pairs became publicly available in 2001 [19, 20], a very precise physical coordinate system for
genomic positions has come into common use. The system simply identifies a position by its
chromosome and base pair number in the reference sequence, starting from a specified end of
the chromosome. The format in text is usually “chromosome:base pair”, e.g chr8:117,700,001.
Since the reference sequence is periodically updated with corrections and previously not
assessed “holes in the assembly”, a version number of the reference sequence (such as hg18,
hg19) must also be stated for the coordinates to be unambiguous.
1.8 Heritability and heritable traits
Heritability is a measure of the proportion of variance in phenotype (disease or trait) in a
population that can be explained by genetic factors. It can be estimated by studying the
phenotypic similarity of individuals of known (genotypic) relatedness, for example twin and
parent–offspring pairs.
The narrow sense heritability is defined as the proportion of phenotypic variance in a
population that can be attributed to additive genetic factors, with the underlying assumption
of contributions coming from a large number of independent loci of small, linear, and additive
effect. For qualitative traits (e.g. binary disease status), the population phenotypic variance
refers to the variance of an underlying continuous liability scale, where individuals with
liability over a threshold value are affected, while those with lower liability are not [21].
Traits and diseases with a high narrow sense heritability have generally been assumed to
be fertile grounds for disease gene hunting. However, as results from large GWAS of common
complex traits started to roll in, the variance explained by the reported associated markers
was consistently lower than initially expected [22]. This phenomenon has sparked a lively
debate on where the missing heritability is to be found.
A number of explanations for the discrepancy have been proposed. One line of arguments
holds that variants explaining the missing heritability are there, just waiting to be found.
Mechanisms supporting this standpoint are for example that most reported GWAS SNPs
are most likely not the functional variant, but in LD with it, diminishing the apparent
variance explained. In the same spirit, it has been suggested that rare variants, and other
classes of variation such as CNVs, that are not well captured by the markers on common
SNP chips, are responsible. Since GWAS methods assume that common disease is caused
by common variants, rare variation may slip by unnoticed [23]. Another line of arguments
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addresses the heritability estimates themselves, suggesting that deviations from additivity of
effects within and between loci may lead to overestimation of a trait’s heritability, thereby
creating “phantom heritability” which can never be completely explained by the actual disease
markers [24].
Both these approaches to the missing heritability problem probably hold some truth, and
future studies will most likely both reevaluate current heritability estimates, find rare variants
of larger effect, and zoom in on variants previously only seen by means of LD. It would not
be hugely surprising if the genetic architecture of complex disease turned out to be – complex.
However, even under the simplifying assumptions underlying GWAS, important, replicable
and biologically plausible findings have been made.
1.9 Omics and computing
Some of the very earliest electronic computers in the 1950s were used for linkage analy-
sis [10]. Later, algorithmic developments (for example shotgun sequencing) and increase
in computing power made possible the assembly of the first human reference genome [20].
Fruitful collaborations between biologists and mathematicians have been frequent through
history – an early example being G. H. Hardy’s well-known letter to Science on the expected
genotype proportions in a randomly mating population under Mendelian inheritance rules
(today recognized as Hardy-Weinberg equilibrium) [25].
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2 The diseases
The studies in this thesis focus on four different diseases: bipolar affective disorder, schizophre-
nia, prostate cancer, and testicular germ cell tumor. Although seemingly disparate, these
diseases have a number of features in common, which make them very interesting from a
human geneticist’s perspective. First, all four diseases have been shown to have a high
heritability, which means that a sizable portion of disease risk is likely due to genetic factors.
Second, all four diseases have a complex mode of inheritance, with no currently known major
disease locus following Mendelian rules of inheritance. Finally, all four diseases considerably
affect public health, and severely impact the lives of those affected.
A short description of the current state of epidemiological research, especially genetic
epidemiology, for the diseases under study follows.
2.1 Bipolar affective disorder and schizophrenia
Bipolar affective disorder (BPAD) and schizophrenia (SZ) are psychiatric disorders with
severe impact on the lives and wellbeing of patients and their families. Both diseases are most
often diagnosed in early adulthood [26]. Though BPAD and SZ have long been regarded as
separate diseases, epidemiological investigations of their co-occurrence in pedigrees [27], and
high-throughput molecular genetic studies [28], have suggested that they share genetic risk
factors. It has therefore been suggested that the dichotomy between the diseases is false, and
that they should instead be considered as part of a wider spectrum of mood, psychosis, and
autism spectrum disorders [29].
BPAD is characterized by at least one episode of mania, or mixed mania/depression (Bipo-
lar type I), or hypomania (Bipolar type II), in combination with recurrent episodes of major
depression [26]. SZ on the other hand is characterized by persistent or recurring delusions,
hallucinations, disorganized speech, and/or catatonic behavior and negative symptoms such
as affective flattening, alogia (poverty of speech), and avolition (an inability to participate in
goal-directed activities) [26]. For a formal SZ diagnosis, the symptoms need to last for at
least six months, and no mood disorder symptoms should be present. If mood symptoms
(manic, depressed or mixed episodes) do occur, the patient will instead be diagnosed with
schizoaffective disorder (SA).
Incidence and mortality
Both BPAD and SZ have long been thought to have a worldwide lifetime prevalence of
approximately 1% each. More recent studies have updated these estimates somewhat.
Systematic reviews of current incidence and prevalence studies of SZ found a median lifetime
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morbid risk of 0.72%, but with much variation between studies (inter-quartile range 0.47%–
1.7%) [30]. Standardized mortality rates indicated a 2.6-fold higher all-cause mortality for SZ
cases compared to the general population [30].
An eleven-nation study of BPAD prevalence coordinated by the World health Organization
used a common diagnostic interview procedure to find cases in population-based samples from
all eleven countries (Colombia, India, China, Brazil, Bulgaria, Lebanon, Mexico, Romania,
Japan, New Zealand, and the United States). The overall lifetime prevalence was estimated to
0.6% for BPAD type I, and 0.4% for BPAD type II [31]. Prevalences for both subtypes varied
from almost 0 in some countries up to 1% in others. These estimates are lower than those
previously reported. The excess mortality for BPAD patients has been estimated in a large
Swedish study to 2.5-fold in men and 2.7-fold in women (standardized all-cause mortality
ratios) [32]. These figures are very similar to those for SZ, and indicate that both disorders
not only lower quality of life, but can actually be lethal.
Risk factors
In the aforementioned systematic review of SZ incidence and mortality, incidence estimates
differed between males and females, with a 1.4:1 rate ratio (higher in males). Furthermore,
incidence was found to be higher among migrants than in native-born individuals (median
rate ratio 4.6) [30]. Studies have also shown SZ incidence to be elevated in urban areas
compared to rural, and in persons born in winter and spring compared to those born in the
summer and fall [33].
There is little consensus on which non-genetic risk factors, if any, influence the risk of
BPAD. A systematic review of around 100 previous studies found no indisputable evidence
for any of a large number of investigated risk factors except for a family history of the disease,
but suggested that childbirth may trigger disease onset [34]. A later study indicated that
disease risk in offspring increased with increasing paternal age [35].
Genetic epidemiology
Both SZ and BPAD are often cited as highly heritable traits. A study of BPAD and SZ in
the Swedish population found an offspring relative risk of 9.9 and a sibling relative risk of
9.0 for SZ, and an offspring relative risk of 6.4 and a sibling relative risk of 7.9 for BPAD.
The heritability was estimated to 64% in SZ and 59% in BPAD. Interestingly, significant
cross-disease risk increases were also observed, such that relatives to BPAD patients had an
increased risk of SZ, and vice versa [27].
The current state of psychiatric genetics for a number of diseases, including BPAD and SZ
was recently reviewed by Sullivan and colleagues [36]. Briefly summarized, the many linkage
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and candidate gene studies that have been performed for BPAD and SZ have rendered results
that, though initially exciting, later turned out to be difficult to replicate in independent
materials. This could be due to, for example, heterogeneity in the causal mutation between
pedigrees and populations, lack of statistical power in the replication studies, or false positive
findings in the initial studies.
A well-known early linkage study of psychiatric traits is that of a large Scottish pedigree
with high prevalence of psychiatric disorders, mostly SZ, but with some pedigree members
affected by BPAD or recurrent unipolar depression. A gene-disrupting translocation from
chromosome 1q42.1 to 11q14.3 was found to segregate with SZ [37], and the disrupted
transcripts were dubbed DISC1 and DISC2 for “Disrupted in Schizophrenia”. Replication
of this finding using association analysis of common variants in the region and a large case-
control sample has been attempted, but no significant association could be seen [38]. DISC1
variation is still being studied for association with SZ and other traits, and the validity of the
initial finding has been questioned, indicating the difficulties in reaching consensus on genes’
involvement in complex disease etiology [39].
Some regions (22q11, 15q13) have been shown to have recurrent CNV events (deletions or
duplications) in SZ cases, and the overall genomic burden of CNV events has furthermore
been shown to be higher in SZ cases [40]. A higher CNV burden in cases has also been
reported in BPAD, but the finding may be limited to cases with early onset disease [36].
Results from one of the largest studies to date of SZ genetics was published by the
Schizophrenia Psychiatric GWAS Consortium in 2011 [41]. SNP data from several case-
control study samples were pooled into a “mega-analysis” sample of 9,394 cases and 12,462
controls, and the strongest associations from this stage were analyzed in an even larger
replication sample of 8,442 cases and 21,397 controls. This resulted in seven replicating risk
loci, of which five were novel. The two previously reported risk loci were located in the major
histocompatibility complex region (6p21.3–22.1), and in the gene TCF4 on 18q21.2, while
the new loci mapped to the regions 1p21.3 (near sequence for the transcribed microRNA gene
MIR137 ), 10q24.32 (several genes in the region), 8q21.3 (nearest gene MMP16 ), 8p23.2 ( in
the gene CSMD1 ), and finally 2q32.3 (nearest transcript is the non-coding RNA transcript
PCGEM1 ).
A similar study of BPAD was also performed recently, coordinated by the same consortium
as the SZ mega-analysis. A discovery sample of 7,481 cases and 9,250 controls was analyzed,
and 34 SNPs were selected for replication in 4,496 independent cases and 42,422 controls.
The study replicated the association in CACNA1C, first reported in a meta-analysis of the
STEP-BD and the Wellcome Trust Case-Control Consortium datasets [42], and further added
the ODZ4 locus to the list of established BPAD risk genes [43].
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Both the studies by the Psychiatric GWAS consortium referenced above then went on to
report the results of an analysis pooling the BPAD and SZ case groups, and comparing them
to a common control group. BPAD risk associations in or near the genes CACNA1C, ANK3,
and the ITIH3-ITIH4 region were strengthened when adding the SZ cases to the analysis,
indicating that these could be shared susceptibility genes between the two diseases [41, 43].
2.2 Prostate cancer
Incidence and mortality
Prostate cancer (PC) is the second most common cancer diagnosis in men worldwide, and
the most common in economically developed countries (using the International Agency for
Research on Cancer’s coarse definition from the GLOBOCAN 2008 report, “more developed
regions” include all of Europe, Northern America, Australia, New Zealand, and Japan, while
the “less developed regions” include all of Africa, Asia excluding Japan, Latin America and
the Caribbean, Melanesia, Micronesia, and Polynesia) [44].
There is much variation in the PC incidence rates between countries, with an approximately
25-fold higher incidence in the highest-ranked region Australia/New Zealand than in the
lowest-ranked region South-Central Asia [44]. These differences are most likely in part due to
different underlying national rates of tumorigenesis, but also due to differences in rates of
discovery in clinics, and a big part of that difference most likely due to differences in use of
Prostate Specific Antigen (PSA) testing and biopsy procedures. Mortality varies less between
the different regions, but an order of magnitude still separates the regions with the highest
mortality rates (Caribbean) from the lowest (Eastern Asia) [44].
The situation in Sweden resembles that of many European and North American countries
with an incidence that has been increasing rapidly starting in the 1990s, following the
introduction of the PSA test. Meanwhile, PC mortality has been more or less constant over
the past half century (Figure 4, data from NORDCAN [45]).
Prostate specific antigen testing
The prostate-expressed glycoprotein PSA was shown to be a sensitive serum biomarker for
PC diagnosis and progression in 1987 [46]. The test lacks in specificity, since patients with
benign prostate hyperplasia (BPH) also have elevated serum PSA levels. Nevertheless, PSA
testing has since become immensely popular, and much of the increased PC incidence in
developed countries may be attributable to increased PSA testing [47]. Despite there being
no formal PSA screening program in Sweden, the current extent of PSA testing can be seen
as an ad hoc and uncontrolled screening program. A recent study of the prevalence of PSA
12
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Figure 4 – Prostate cancer incidence and mortality in Sweden 1960–2009. Rates are the
number of new cases/deaths per 100,000 person-years, standardized to the World Standard
Population. Points represent actual reported rates, while lines are LOESS smoothed estimates.
Data from NORDCAN [45].
testing in Stockholm county reported that in 2011, 46%, 68%, and 77% of men in the age
groups 50–59, 60–69, and 70–79 years respectively had performed at least one PSA test in
the last 9 years [48].
Two large randomized trials of the impact of organized PSA testing on PC mortality and
overall mortality, the European Randomized Study of Screening for Prostate Cancer (ER-
SPC) [49] and the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (PLCO) [50]
studies, have recently published results from 11 and 13 years of follow-up respectively. Results
were conflicting, with ERSPC reporting a statistically significant improvement of PC mortality
in the screening group, while PLCO reported no significant improvement. The difference
between the results may be due to a higher degree of opportunistic screening in the control
arm of PLCO, or to a number of other differences between study designs and the underlying
populations. The dispute on whether organized PSA screening is advisable is thus far from
settled.
Risk factors
Besides genetic risk factors including family history, which will be discussed separately, there
are a number of established and suspected risk factors for PC. The established risk factors
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include ethnicity (e.g. low incidence in Asian populations, high in Northern Europe, and
very high in African-Americans in the USA) and age (almost no one is diagnosed with PC
before age 45, but the incidence increases rapidly with age after that) [51]. Dietary risk
factors for PC have been investigated in many studies, but results are not yet conclusive.
Observational studies have among other things suggested increased PC risks from high dietary
fat and red meat intake [52], and protective effects from fatty fish [53], phytoestrogens [54],
vitamin E, selenium, tomatoes and lycopene (an antioxidant found in high levels in tomatoes),
cruciferous vegetables (such as cabbage, broccoli, cauliflower, and brussels sprouts), and green
tea [52]. Some of these effects have support from in vitro studies, but the evidence from large
randomized clinical trials for chemoprevention has so far not been convincing [52].
Genetic epidemiology
Prostate cancer is one of the most heritable forms of cancer. Studies of twins have estimated
the proportion of variance in PC risk that is due to genetic factors to 42%, and a family
history of prostate cancer is one of the strongest known risk factors for the disease [55, 51].
Linkage and candidate gene studies have not resulted in many replicated findings, symp-
tomatic of a disease with complex inheritance patterns. Some genetic variants in the loci
BRCA1 and BRCA2 strongly associated with breast cancer risk have also shown association
to prostate cancer risk [56].
Great advances in the search for PC susceptibility loci have been made with the feasibility
of genome-wide association studies. GWASs and GWAS meta-analyses have uncovered several
loci consistently associated with PC risk during the last few years, albeit most with small
effect sizes. The current landscape of established genetic associations with prostate cancer has
been recently reviewed by Goh and colleagues [57], and consists mostly of common variants
of small effect, derived from GWAS analyses.
Since the review by Goh et al was published, a newly discovered relatively rare single
nucleotide variant in the gene HOXB13 has been associated with a high relative risk of
prostate cancer [58]. This association was replicated in a large Swedish case-control sample
in paper II of this thesis, and will be discussed further below.
2.3 Testicular germ cell tumor
Incidence and mortality
Most malignant neoplasias (approximately 95%) in the testes are germ cell tumors [59].
Although testicular germ cell tumor (TGCT) is an overall rare disease, with approximately
6.2 new cases per 100,000 person-years in Sweden (average between years 2000 to 2009, data
14
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Figure 5 – Testicular cancer incidence and mortality in Sweden and Norway 1960–2009. Rates
are the number of new cases/deaths per 100,000 person-years, standardized to the World
Standard Population. Points represent actual reported rates, while lines are LOESS smoothed
estimates. Data from NORDCAN [45].
from NORDCAN [45]), its incidence has been increasing over time worldwide, nearly doubling
since the 1960s [59]. Furthermore, it is the most commonly occurring solid tumor in young
men (between approximately 15–35 years of age) in the Nordic countries [45], with similar
patterns seen for North America, Western Europe, and Australia [60]. Figure 5 shows the
incidence and mortality of TGCT since 1960 in Sweden and Norway, age-standardized to the
World Standard Population.
Due to an uncommonly high sensitivity of TGCT cells to combination chemotherapy
including cisplatin, most patients since the mid-1980s (when the treatment regimen was
introduced) survive their disease. This holds true even for late stage and metastatic disease [59].
The 5-year relative survival (with 95% confidence intervals) was 94% (89–98) in Sweden and
90% (86–96) in Norway for testicular cancers diagnosed between 1999 and 2008 [45].
Risk factors
Even though most TGCTs are thus curable, it is still of interest to understand the underlying
etiology, and if and how they could have been prevented. Besides the immediate use of newly
discovered risk factors for risk assessment, some insights in the disease mechanisms could
translate to other, more lethal cancers, and increase our understanding of their etiology, and
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in the very long run provide clues on how to cure them. To this end, several studies of the
epidemiology of TGCT have been performed.
Among the established or suggested risk factors for TGCT we find undescended testes
(cryptorchidism), a previous (contralateral) TGCT, hormone exposures in utero, perinatal
factors, and a family history of the disease [61]. Male subfertility has also been associated
with increased TGCT risk, an association which remained when excluding subfertility due to
cryptorchidism [62].
Genetic epidemiology
First-degree relatives of TGCT patients have a highly increased disease risk, with one large
study of the Swedish population reporting a standardized incidence ratio of 3.8 (95% CI
2.2–6.2) for sons of cases and 8.6 (95% CI 6.4–11.3) for brothers of cases [61]. The heritability
of TGCT has been estimated in family studies to 25% (95% CI 15–37), which is one of the
highest heritabilities among cancer diagnoses [63]. This indicates that genetic factors play an
important role in the disease etiology.
Several genetic associations have been reported for TGCT risk. The 1.6 mega base
microdeletion gr/gr on the Y chromosome was found in year 2005 to be associated with
a two- to threefold increase in TGCT risk [64]. More recent findings from GWAS efforts
include associations within the genes activating transcription factor 7 interacting protein
(ATF7IP), BCL-2 antagonist/killer 1 (BAK1), doublesex and mab-3 related transcription
factor 1 (DMRT1), KIT ligand (KITLG), sprouty homolog 4 (SPRY4), and telomerase reverse
transcriptase (TERT) [65, 66, 67, 68]. A meta-analyses of current GWAS efforts, results
of which were presented at the 2012 annual meeting of the American Society for Human
Genetics, implicated four additional loci associated with TGCT risk [69]. These were located
in chromosomal regions 4q22.2 (in the gene HPGDS ), 7p22.3 (in the gene MAD1L1 ), 16q22.3
(in the gene RFWD3 ), and 17q22 (in or near genes TEX14, PPM1E, and RAD51C ). These
results are however to be considered as preliminary, since they have not yet been published
in a peer-reviewed journal.
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3 Aims
The general aim of this thesis was to increase knowledge of disease-related genetic and
metabolomic variation in heritable complex diseases and disorders, by applying appropriate
computational and statistical methods to large datasets in a molecular epidemiological
framework.
The specific aims of this thesis, each corresponding to one of its four component papers,
were:
• To find rare, highly penetrant, disease-associated genetic variants in bipolar disorder,
through a comprehensive assessment of genetic variation in families with high prevalence
of the disease, and to follow up these findings in a larger case–control sample of bipolar
disorder and schizophrenia.
• To assess the prevalence and penetrance of a newly discovered rare genetic variant,
associated with a high risk for developing prostate cancer, in two large Swedish case-
control samples, and to further assess its impact on lifetime risk of the disease.
• To replicate and further characterize findings from genome-wide association studies
of testicular germ cell tumor, through genotyping and analyzing tagging SNPs in
case-parent triads and unrelated cases and controls.
• To study whether metabolites in serum, detectable trough ultra-performance liquid
chromatography–mass spectrometry (UPLC-MS), can be used as biomarkers, in order
to separate prostate cancer cases from healthy controls, and indolent prostate cancer
from more aggressive disease.
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4 Materials
Patient materials for the papers in thesis were assembled from multiple large case-control
and family-based study samples.
4.1 The NIMH Genetics Initiative
The National Institute of Mental Health (NIMH) Bipolar Disorder Genetics Initiative [70]
has established a repository of data and biomaterials (DNA and lymphoblastoid cell lines)
from pedigrees with at least one proband affected by BPAD, with resources available upon
request for qualified researchers investigating BPAD genetics. Data collection began in 1991,
and is still ongoing. From 1996 and onwards, the project has been accepting data requests.
In addition to the biological samples and cell lines, the project database includes anonymous
data on family structure, age, sex, vital status, psychopathology, diagnosis, and other
clinical information, as acquired through relatives, medical records, and directly through the
Diagnostic Interview for Genetic Studies (DIGS) structured interview tool.
For paper I, a data request was granted for pedigrees with available genome-wide microsatel-
lite data from previous linkage analyses. Previous reports had only published compound
linkage results from entire waves of pedigrees. In order to select the most promising pedigrees
for rare variant discovery, we therefore performed family-wise linkage analyses using the
available markers. Based on these analyses, a request for DNA from 277 individuals in 48
pedigrees was made and granted.
Genome-wide SNP genotypes for 592,275 markers were then successfully generated for 275
of the DNA samples using the Illumina Human 610 quad chip, and analyzed further in house.
4.2 Case-control CNV data from publications and collaborators
Stage 2 of the analyses in paper I involved a large, pooled sample of CNV genotypes for
cases affected by BPAD, SZ, or SA, and control samples. These genotypes were assembled
partly from samples available to collaborators, partly from complete datasets published as
supplementary information to original articles, and partly from direct contact with authors of
studies on copy-number variation in psychiatric or other disease. A full listing of the sample
sources can be found in table 1 of paper I. Since some of the included studies reused the same
samples, care was taken when assembling the data to only count each individual once. In
total, we assembled data from 3,683 BPAD cases, 7,242 SZ or SA cases, and 16,747 controls.
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4.3 CAPS
Cancer of the Prostate in Sweden (CAPS) is a population-based case-control study of genetic
and dietary PC risk factors. Patients were identified from regional cancer registries between
2001 and 2003. Control subjects were recruited concurrently using the Swedish population
registry. Controls were selected, randomly from the total male population, to match the
expected age (in five-year age groups) and geographic distribution of the cases.
Information and biomaterials collected for each participant included a blood sample, and a
questionnaire with questions concerning family history of PC, diet, and lifestyle. For the cases,
data also include date of diagnosis, diagnostic PSA measurement, and tumor characteristics.
Blood samples from cases were taken on average five months after the time of diagnosis.
The sample database has been continuously updated with genotypes of new potential risk
markers for PC over the years. One of the most recent updates provided genotypes for a rare
coding variant (and surrounding common variants) in the gene HOXB13, rs138213197, which
is further discussed in paper II.
Recently genome-wide SNP genotypes from the Affymetrix 500k and 5.0 chips were added
to the body of data available for the sample. These genotypes have been successfully used
in meta-analyses of PC risk and aggressiveness [71, 72], and were studied in paper IV of
this thesis for their relation to serum metabolomic features associated with PC. Finally, as
previously mentioned, a subsample consisting of controls (188), cases with indolent disease
(188), and cases with aggressive disease (99), was selected for analysis of serum metabolomics
using UPLC-MS, which is further described in paper IV. The numbers of cases and controls
with the different types of molecular data available are presented in table 1.
Available data Cases Controls Used in paper
Blood sample, questionnaire and registry data 3,161 2,149
HOXB13 G84E genotypes 2,805 1,709 II
Genome-wide SNP genotypes 1,932 994 IV
UPLC-MS spectrograms 287 188 IV
Table 1 – The CAPS study sample of PC patients and population controls.
4.4 Stockholm-1
Stockholm-1 is a study of men in Stockholm, Sweden, who underwent a prostate biopsy
examination between 2005 to 2007.
Patients were identified through patient registries, and invited to participate in the study
by providing a blood sample and filling in a questionnaire regarding family history of PC. In
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total 5,241 men (2,135 biopsy positive cases and 3,106 biopsy negative controls) consented to
participate and provide the required materials. In addition to the data provided directly by
the patients, the study includes information on PSA levels as measured before the biopsy was
taken (obtained by registry linkage to the PSA testing laboratories in Stockholm), biopsy
results from linkage to the Pathology laboratory, and cancer status through linkage to the
regional cancer and prostate cancer quality registry.
The sample was first used by Aly and colleagues to show that adding a score based on 35
PC risk SNPs to a risk prediction model based on PSA, age, and family history of PC could
increase the specificity of the prediction model without reducing sensitivity [73].
For paper II in this thesis, the rare coding variant rs138213197 (G84E) in the gene
HOXB13 was genotyped with a number of surrounding common SNP markers in order to
assess their impact on PC risk. For this study, patients who had displayed biopsy results
positive for PC were designated as cases, while the biopsy negative men were used as controls.
2,098 cases and 2,880 controls were successfully genotyped and analyzed. Furthermore,
genotypes for the established risk SNPs studied by Aly and colleagues were available and
investigated for their ability to predict lifetime PC risk in combination with the moderately
penetrant HOXB13 variant.
4.5 GENETEC
The GENETEC study sample of TGCT patients and their parents was collected in Sweden
and Norway between 2008 and 2010. Eligible patients were identified through national cancer
and patient registries. All men with a TGCT (ICD-10, C62) diagnosis between 1995 and
2006 in Sweden and between 1990 and 2008 in Norway were invited by mail to participate in
the study. Patients who chose to participate were asked for permission for us to contact their
biological parents for invitation to participate in the study. DNA was collected from saliva.
Both patients and their parents were sent the same DNA self-collection kit with instructions
to “spit in the tube” and return the sample by prepaid mail.
The number of participating TGCT patients and parents per country are displayed in
table 2. Even though Sweden has almost twice the population of Norway, the higher rate of
Norway Sweden Total
TGCT cases 974 1,188 2,162
Full triads 483 521 1,004
Dyads (mothers/fathers) 192 (150/42) 248 (178/70) 440 (328/112)
Singletons 299 419 718
Table 2 – The GENETEC study sample of TGCT patients and their parents.
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TGCT in Norway led to a sample that was almost balanced between the countries. Average
age at diagnosis among TGCT cases was 32 years (range: 15 to 65 years).
Kristiansen and colleagues published the first results from this study sample, in a genetic
association study of SNP variation in candidate genes in sex hormone pathways in relation to
TGCT [74].
4.6 TwinGene
The TwinGene study sample is a population-based sample of Swedish twins (monozygous and
dizygous) identified from the Swedish twin registry, and ascertained between 2004 and 2007.
Study participants provided information about zygosity, lifestyle and health by questionnaire,
and a blood sample for extraction of DNA and other blood components. The total sample
size was 12,591 individuals, with year of birth ranging from 1911 to 1958 [75]. A majority
of the sample (9,836 individuals) were genotyped genome-wide using the Illumina Human
OmniExpress bead chip, providing genotype information for about 730,000 SNP markers per
individual.
For paper III of this thesis, a subsample of the TwinGene cohort was selected to act as
population controls in the case-control analysis of TGCT risk SNPs. We created this control
group by extracting all unrelated male subjects among the samples that were successfully
genotyped. Thus, if a twin pair consisted of a brother and a sister, we included the brother.
If the twin pair was all male, one of the brothers was extracted (assuming both had been
successfully genotyped). Through this selection procedure, 3,919 control samples were included
in the analyses for paper III. As for the case-parent sample, this control group was also used
in the study of genes in hormone pathways by Kristiansen et al. [74].
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5 Methods
5.1 In vitro
This section describes the biochemical methods that were used to generate data from biological
samples.
5.1.1 Genome-wide SNP genotyping
In the early days of SNP genotyping, the process was manual and tedious. Technical advances
quickly improved the procedure, and more and more markers could be genotyped in parallel
in ever shorter timespans. The SNP genotypes used for association testing in the TwinGene
sample in paper III, the CAPS sample in study IV, and for assessment of CNVs in paper I,
were all measured using genome-wide SNP chips, a technology which enabled the genome-wide
association study (GWAS) era.
Based on the human reference sequence, and the database of known SNP locations,
short primer DNA sequences are synthesized and placed on specific locations on a small
chip. Modern SNP chips can measure genotypes for up to a few million markers in parallel.
Fragmented sample DNA is then hybridized to the primers, and based on either allele-specific
base extension or allele-specific binding, an optical signal is generated. The signals are
digitized by a specialized scanner instrument, and computer algorithms use the intensity
and color of each signal to determine individual genotypes. A comprehensive review of the
technologies underlying current GWAS genotyping platforms can be found in [76].
5.1.2 Candidate SNP genotyping
When only a small number of specific SNPs are of interest, genotyping markers across the
entire genome on a SNP chip is a waste of time and resources. Before the GWAS era,
genotyping a few markers at a time was the only way to acquire genetic data. Today, similar
but much optimized methods are used as a quick and non-expensive complement to genome-
wide SNP chips. The main uses today of these “oligoplex” technologies are replication studies
of GWAS findings, candidate gene studies, and clinical genotyping.
The Sequenom iPLEX MassArray technology was used in papers II and III of this thesis
for replication of previously published genetic associations. The platform uses allele-specific
base extension in the genotyping process, but instead of optical signaling, alleles are detected
by mass spectrometry [76].
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5.1.3 Ultra-performance liquid chromatography–mass spectrometry
In order to measure the abundances of a large slice of the spectrum of molecules present in
human serum (human blood with cells and coagulant factors removed), we applied ultra-
performance liquid chromatography coupled with mass spectrometry (UPLC-MS) for the
analyses in paper IV.
The UPLC-MS technique is a method which spreads molecules in a sample along two
dimensions. The first step (UPLC) separates a sample by a gradient of molecule size and
solubility in a solvent fluid, pumped through a column. This generates a retention time (RT)
axis (different molecules take varying amounts of time to move through the UPLC column
due to differences in size and solubility).
At the end of the UPLC column, the sample moves to the mass spectrometry step, where
an electrical voltage is applied to fling molecules across a small gap, and smash them into
an ion detector. The molecules land on different locations on the detector depending on
the relation of their molecular mass to their electrical charge, the mass/charge ratio (M/Z).
For each molecule eluting through the column and being measured by the ion detector, an
intensity which is proportional to the abundance of the molecule in the serum is recorded,
along with its M/Z and RT values.
The resulting three-dimensional data matrix is further processed to transform data from
the continuous M/Z and RT spectrum to a list of “peaks” corresponding to detected ions, and
their intensity for each serum sample analyzed. This process is described under the following
in silico section.
5.2 In silico
This section briefly describes the statistical, epidemiological, and computational methods
which were used to manage, analyze, visualize, and interpret the data.
5.2.1 Linkage analysis
In paper I, family-wise linkage analysis using microsatellite and SNP markers (for the pedigrees
genotyped on SNP chips) was performed using GENEHUNTER-PLUS [77]. Recessive,
dominant, and nonparametric models were used.
5.2.2 Copy number detection from SNP chip data
For generation of genome-wide CNV data from probe intensity data from genome-wide SNP
chips, we used the software package PennCNV [78]. PennCNV uses a hidden Markov model to
detect genomic copy number state from the absolute intensity (log R ratio, LRR) and relative
23
B Allele Frequency on chr 3 for sample ClinTcnv5 (Unrelated cases)
BP
BA
F
  0.00
  0.25
  0.50
  0.75
  1.00
l
ll
l
l
l
ll
l
l
l
l
l
l
l
ll
lll
ll
l
l
l
l
l
l
l
ll
l
ll
l
ll
l
l
l
l
l
l
l
l
l
l
l
ll
ll
lll
ll
l
l
ll
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
ll
lll
l
l
ll
l
l
l
l
ll
l
l
lll
ll
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
llll
l
l
l
l
l
l
l
lll
l
l
l
ll
l
l
l
l
l
ll
l
l
ll
l
l
l
ll
l
l
ll
l
l
ll
ll
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
lll
l
l
l
l
l
ll
l
l
lll
l
ll
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
lll
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
ll
l
l
l
l
lll
l
ll
65200000 65400000 65600000 65800000 66000000
B Allele Frequency on chr 3 for sample ClinTcnv6 (Unrelated cases)
BP
BA
F
  0.00
  0.25
  0.50
  0.75
  1.00
l
llll
lll
l
l
l
l
ll
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
lll
l
l
ll
l
l
l
l
l
l
ll
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
ll
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
lll
l
l
l
l
l
l
l
l
l
ll
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
ll
l
ll
ll
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
ll
ll
l
l
l
l
l
lll
l
ll
ll
l
l
l
ll
l
l
ll
l
l
llll
l
ll
l
l
llll
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
ll
l
l
l
l
l
l
ll
ll
l
l
ll
l
l
ll
l
l
l
l
l
l
ll
l
lll
ll
l
l
ll
l
l
l
lll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
ll
l
l
l
ll
l
ll
l
l
l
l
ll
l
l
l
l
l
l
l
ll
l
l
l
l
l
lll
ll
llll
lll
l
l
ll
l
ll
l
l
l
l
l
65200000 65400000 65600000 65800000 66000000
Log R Ratio on chr 3 for sample ClinTcnv5 (Unrelated cases)
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Log R Ratio on chr 3 for sample ClinTcnv6 (Unrelated cases)
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Figure 6 – SNP data for CNV detection by PennCNV. The left column shows a duplicated
region (copy number is 3). The upper BAF panel shows clusters for the four genotypes AAA,
AAB, ABB, and BBB for a chromosomal segment where the lower LRR (intensity) panel shows
an increase in signal strength. In the right column a deletion event has occurred (copy number
is 1). The upper BAF panel shows clusters for the two genotypes A and B for a chromosomal
segment where the lower LRR panel shows a decrease in signal strength.
intensity of allelic probes (B allele frequency, BAF) sequentially along the chromosomes.
Figure 6 displays example raw data for a duplication and a deletion as detected by PennCNV.
5.2.3 GWAS quality control and association testing
Because of the large number of tests performed in a standard GWAS, meticulous quality
control of data is essential for controlling the number of false positive findings. Standard
steps of quality control include the exclusion of individuals and markers with a high rate of
missing genotypes, tests for deviations from Hardy–Weinberg equilibrium, which may indicate
genotyping problems, and the assessment of and adjustment for population substructure in
the sample, which may inflate false positive rates. Standard protocols have been developed
for this quality control procedure [79], but must often be adapted to be of use to any given
research group.
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It has been said that standard GWAS data quality control is a sort of “post mortem”
rescue attempt of a failed experimental design, and that more care should be taken to properly
randomize case and control samples with regard to analysis batch parameters [80]. Doing
this would make many standard data exclusion steps unnecessary, because the case-control
analysis is not confounded by randomized factors. However, because GWAS data sets are
often re-used for analyses not originally planned, pooled in meta- and mega-analyses, and
because a large number of GWAS data sets have already been genotyped, the post-genotyping
quality control process will be in use for a long time.
Standard tools for quality control and analysis of GWAS data include the PLINK [81]
software toolbox, and R [82].
For the association analyses in paper II, we used logistic regression modeling in R to
calculate odds ratios (OR), approximating relative risks, and 95% confidence intervals (CI).
For the haplotype analyses in the same paper, we used PLINK. Data quality control in paper
III used R and PLINK, which is also useful when managing and cleaning candidate gene
data. Finally, for the genetic association step of study IV, PLINK was used to perform linear
regression analysis of metabolomic features and SNP markers.
5.2.4 SNP imputation
In order to artificially increase the marker density of the candidate gene regions of paper III,
we performed genotype imputation using the Beagle software package [83, 84]. Beagle uses
information on family structure and local LD together with a densely genotyped reference
panel (1000 genomes) to infer markers which were not directly genotyped with good accuracy.
5.2.5 Lifetime risk, adjusted for competing risks
alive and well
prostate cancer
dead
(other cause)
λ
µ0
Figure 7 – State diagram for the competing risk model used in paper II. µ0 and λ are the
transition rates between the different states: µ0 is the other cause mortality rate, and λ is the
prostate cancer incidence rate.
25
In paper II, we estimated the effects of the HOXB13 G84E mutation on lifetime absolute
risk of prostate cancer in Swedish men. In order for the estimates to be applicable to the
real world, we needed to take into account the competing risk of other cause mortality. This
is especially important for a disease with late age of onset such as PC, since other cause
mortality is considerable in older age groups.
We first used the Swedish total population registries of cancer incidence and causes of
death (Statistics Sweden) to acquire the national rates of PC incidence and other cause
mortality (the latter by subtracting the number of PC deaths from the all-cause mortality).
With population rates of PC incidence and other cause mortality available, we estimated
the cumulative hazard of a PC diagnosis from birth to age t years, adjusting for competing
risks (other cause mortality) by numerically solving the differential equation system
s′(t) = −(λ+ µ0)s(t)
c′(t) = λs(t)
s(0) = 1, c(0) = 0
for c(t), where s(t) is the cumulative survival from age 0 to age t, c(t) is the cumulative PC
incidence from age 0 to age t, λ is the group specific incidence rate for G84E carriers and
non-carriers (estimated from the logistic regression odds ratios, adjusted for the sampling
age strata, and the population incidence), and µ0 is the other cause mortality. The possible
states and transitions of persons in the analysis is displayed in figure 7. Proportional hazards
between HOXB13 G84E carriers and non-carriers were assumed.
5.2.6 Genetic risk scores
In paper II, we combined the moderately penetrant HOXB13 G84E mutation in a statistical
model with a genetic risk score (also called polygenic risk score) based on known risk loci of
small effect. Such scores were used in an innovative manner to show that many risk loci for
SZ of very small effect are, in compound as a polygenic risk score, associated with BPAD [28].
They have also been used in other efforts including PC risk prediction [73].
Some studies using the risk score approach have simply created the score as a count of the
number of risk alleles carried by an individual, while others have weighted the count at each
marker locus by the per-allele odds ratio, calculated from the same material or from literature
surveys or other samples. The approach we used in paper II was to search the literature for
risk markers, calculate their allelic odds ratios in the Stockholm-1 sample, and then generate
the per-individual scores in the CAPS sample using the Stockholm-1 odds ratios as weights.
In mathematical notation, our score was defined as
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Sj =
1
n
n∑
i=1
log(ORi)aij,
where Sj is the risk score for individual j, ORi is the per allele odds ratio for marker i (out
of a total of n markers), and aij is the number of non-reference alleles (0, 1, or 2) carried by
individual j at marker i. This formula assumes that the risk contributions from each SNP
combine in a multiplicative manner.
5.2.7 Combined family-based and case-control association analysis
For the association testing of paper III, we applied a likelihood-based test able to combine
information from case-parent units with case singletons and unrelated control subjects in
a single powerful test for association. The test is implemented in the software package
UNPHASED [85].
5.2.8 Peak detection for UPLC-MS chromatograms
For the conversion of raw UPLC-MS data to a list of molecular features in paper IV, we
used the software package XCMS [86]. After normalization, averaging intensities over sample
triplicates, and log10-transformation of the detected features, association analyses were
performed by linear regression, and the ANOVA F-test. Peak detection, normalization, and
analysis was performed in the R statistical programming environment [82].
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6 Results and Discussion
6.1 Rare MAGI1 mutations increase risk for BPAD and SZ
In paper I we describe a search in 48 BPAD pedigrees (277 individuals) for rare CNVs
segregating with disease. After CNV detection, variants shorter than 10 kilo base pairs (kb),
and common variants described in the public Database of Genomic Variants (DGV) were
filtered out. After filtering, CNVs were ranked by the number of affected individuals per
family in which they were detected. A CNV of seemingly high penetrance in a large pedigree
(an intronic deletion of ∼200 kb) was found in the gene MAGI1, and this genomic region was
consequently studied further in a large pooled sample of unrelated cases and controls.
Since multiple lines of evidence have indicated that BPAD, SZ and SA may share genetic
risk factors, the decision was made for the case-control replication effort to study cases from
not only BPAD samples, but also those affected by SZ and SA. If the CNVs we investigated
were among the shared genetic risk factors, this approach would then increase the statistical
power of this study. In total, the pooled dataset consisted of 3,683 BPAD cases, or 10,925
cases when pooling the samples of BPAD, SZ, and SA patients, and 16,747 control samples.
The data sources are described briefly in section 4.2, and fully in Table 1 of paper I. Since
many sources only reported variants of 100kb or larger, and the detected variants in our
family sample were well above that threshold, the pooled analysis was limited to variants
exceeding this size limit.
One additional CNV in the region, a duplication of ∼160 kb, was found in two out of
three affected members of another BPAD pedigree in the family sample. We counted this
as one exposed case for the case-control analysis. A further event was detected in a BPAD
case from the Wellcome Trust Case-Control Consortium sample. The pedigree structures of
the two BPAD families with MAGI1 CNVs are displayed in figure 8. When expanding the
case sample to include SZ and SA cases, five additional CNVs were detected in cases from
Figure 8 – BPAD pedigrees in which MAGI1 CNVs were detected.
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Figure 9 – MAGI1 copy-number variation in BPAD pedigrees and BPAD, SZ, SA, and control
samples of unrelated individuals. Red bars represent deletions, blue bars duplications. White
text in the “Cases” section mark diagnoses in carriers. The bottom line shows the extent of
the coding (wide line) and non-coding (narrow line with arrowheads) genomic sequence of the
MAGI1 gene. Genomic coordinates refer to the hg18 reference assembly of the human genome.
the International Schizophrenia Consortium and clinical trial participants from Johnson &
Johnson Pharmaceutical Research and Development.
In all of the 16,747 pooled control samples, only two CNV events affecting the MAGI1
region were detected. Figure 9 displays the genomic location of all the MAGI1 CNVs used
for association testing in this study.
CNV-disease association was tested in the pooled case-control sample using Fisher’s
exact test, with a one sided alternative hypothesis due to the prior hypothesis of MAGI1
CNVs being more common in cases. The pedigree in which the variant segregating with
BPAD was first discovered was not included in any test for association, and the duplication
appearing twice in another pedigree was only counted once. The results for the two analyses
of BPAD cases versus controls, and BPAD, SZ, and SA versus controls are presented in
table 3 (reproduced from paper I).
MAGI1 CNV events were significantly more common in the pooled BPAD, SZ, and
SA case group than in the control population. Due to the rarity of these events, effect
estimates could not be made with high precision, reflected by the very wide confidence
intervals presented. Even larger study samples are needed in order to assess the true impact
of these variants. Nevertheless, the present study strongly supports the importance of the
MAGI1 gene in BPAD etiology.
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Hypothesis Cases Controls Case
CNVs
Control
CNVs
P OR (95% CI)
MAGI1 CNVs more common in cases
BPAD alone 3,683 16,747 2 2 0.15 4.5 (0.5–∞)
BPAD, SZ, and SA 10,925 16,747 7 2 0.023 5.4 (1.3–∞)
Table 3 – Paper I main association results. One-sided P-values and 95% confidence intervals
were derived from Fisher’s exact test.
Limitations of this study include the heterogeneous data sources, with different biochemical
and computational methods employed for CNV calling. This is partly overcome by the
application of a 100 kb lower length limit of CNVs included, since such large events are more
consistently detected across platforms and algorithms. Furthermore, the consistency in size
and inheritance of the CNVs in the discovery pedigree minimizes the risk of the initially
detected variant being a false positive finding.
6.2 The HOXB13 G84E mutation significantly increases PC risk
In paper II, we studied a recently discovered, coding, rare single nucleotide variant in the gene
HOXB13 associated with a highly increased risk of PC (reported OR ∼20) [58]. Because
the initial finding needed to be replicated in an independent sample, and because the initial
estimate of effect size was very uncertain (95% CI 3.5–803, Fisher’s exact test) due to very
few control samples carrying the mutation, we embarked on a replication study using two
Swedish case-control samples of PC: CAPS and Stockholm-1, described in sections 4.3 and
4.4.
The coding G84E variant (SNP ID rs138213197) and flanking common variants were
successfully genotyped in 2,805 cases and 1,709 population controls in CAPS, and in 2,098
biopsy positive cases and 2,880 biopsy negative controls in Stockholm-1.
The G84E variant was found in higher frequencies in both Swedish samples studied,
compared to the US-based samples initially analyzed by Ewing and colleagues. The carrier
frequency in the Swedish control samples was similar to that in the US cases (1.3–1.4%), and
even higher in the Swedish cases. The carrier frequencies found in CAPS and Stockholm-1
are displayed in table 4 along with the main association results.
The higher overall carrier frequency in the Swedish materials allowed us to infer more
precise estimates of the relative risk increase associated with the G84E mutation in Sweden,
and gave very similar estimates of 3.4 and 3.5 in CAPS and Stockholm-1 respectively. This
places the HOXB13 G84E mutation in the hitherto sparsely populated region of uncommon,
moderately penetrant variants on the map of PC-associated genetic variation [57].
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Sample G84E noncarriers G84E carriers Carrier frequency OR 95% CI P
CAPS
Controls 1,685 24 1.4%
Cases 2,675 130 4.6% 3.4 (2.2–5.4) 6.4× 10−10
Stockholm-1
Controls 2,843 37 1.3%
Cases 2,007 91 4.3% 3.5 (2.4–5.2) 2.0× 10−11
Table 4 – Paper II main association results. Odds ratios, P-values and 95% confidence intervals
were calculated by logistic regression.
Age G84E noncarriers G84E carriers G84E carriers, risk score in Q4
60 1.3% (1.1–1.4) 3.9% (2.5–6.2) 6.4% (4.1–10.0)
65 3.3% (3.0–3.6) 9.9% (6.5–15.3) 16.1% (10.6–24.4)
70 6.1% (5.7–6.7) 18.1% (12.1–27.0) 28.4% (19.5–41.5)
75 9.2% (8.6–9.9) 26.0% (17.9–37.7) 39.6% (28.4–55.3)
80 12.0% (11.3–12.8) 32.5% (23.1–45.9) 47.7% (35.6–64.0)
Table 5 – Paper II absolute risk estimates up to certain ages with 95% confidence intervals.
Estimates are adjusted for other cause mortality. Risks were estimated for G84E noncarriers,
G84E carriers, and G84E carriers within the uppermost quartile of a genetic risk score based on
33 established PC risk SNPs.
Using register-based total population data on age-specific mortality and PC incidence, and
the G84E mutation effect estimates from the population-based CAPS sample, we employed
competing risks methods to estimate the lifetime absolute risk of PC in G84E carriers and
noncarriers, adjusted for the competing risk of other cause mortality.
The lifetime absolute risk estimates up to certain ages for G84E carriers and noncarriers
are presented in table 5. According to our model, almost a third of G84E carriers will be
diagnosed with PC by age 80. In addition to the PC risk increase conferred by the HOXB13
G84E variant, we analyzed a model including G84E and quartiles of a genetic risk score based,
on 33 established PC risk SNPs. Table 5 also shows the absolute risk estimates for G84E
carriers within the uppermost quartile of this score, a combination expected to be found in
∼0.3% of the Swedish population. In this group, the estimated lifetime PC risk up to age
80 reached almost 50%. In a hypothetical screening program where genetic markers were
assessed, this group of men could be easily identified and offered more frequent subsequent
screening or even genetic counseling.
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6.3 Six genes are associated with TGCT risk, one modified by
parent-of-origin
In paper III, we performed a combined case-parent, case-control association analysis of
common SNPs in genes previously shown to be associated with TGCT. We furthermore
investigated whether the estimated effects of SNPs were modified by parental sex, and tumor
histological subtype (seminoma or non-seminoma).
118 SNP markers in or near the six genes ATF7IP, BAK1, DMRT1, KITLG, SPRY4, and
TERT were genotyped in 831 case-parent triads, 474 case-parent dyads, and 712 singleton
cases. Genome-wide SNP data, including the regions under investigation, were available
for 3,919 unrelated male controls from the TwinGene project. Using imputation methods,
genotypes were generated for the entire sample for a total of 852 SNP markers passing all
quality control steps, including markers which were directly genotyped.
In a combined case-parent and case-control test for SNP-TGCT association, marker
genotypes in all the investigated genes were found to be significantly associated with TGCT.
The associations remained highly significant after false discovery rate (FDR) adjustment of
P-values for multiple testing.
By gene-wise stepwise logistic regression among genotyped markers, 11 SNPs in total
were found to be associated with TGCT when adjusting for the previously selected significant
markers in the same gene. Three each of these were in the TERT and BAK1 regions, two
in the SPRY4 region, and one each in DMRT1, ATF7IP, and KITLG. Figure 10 shows the
overall association results and markers selected by stepwise regression per gene.
The 11 independently associated SNPs were tested for interaction of the allelic effect
with parental sex, and with the tumor histological subtype (seminoma or non-seminoma)
found in the proband. No markers showed significant statistical interaction with histological
subtype, but one marker in the SPRY4 region had a significantly different effect on disease
risk depending on the sex of the parent from which an allele was inherited.
Specifically, the marker rs10463352, just upstream of the coding sequence for SPRY4,
had an estimated OR of 1.72 (95% CI 1.38–2.15) for maternally inherited G alleles, while
the same estimate for paternally inherited alleles was 0.99 (95% CI 0.70–1.39) (unadjusted
P-value for interaction 0.0013). Thus, the overall allelic effect estimated for this marker was
attenuated by including the paternally inherited alleles.
If the parent-of-origin effect seen for rs10463352 in TGCT holds up for replication in
independent materials, this effect indicates gene silencing by genomic imprinting in males,
or some other mechanism of gene-sex interaction. This is a new aspect of TGCT genetic
epidemiology, and could lead to further insight in disease mechanisms.
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Figure 10 – Main association results of paper III. Black markers were directly genotyped, while
gray markers were imputed. Star-shaped markers were selected in gene-wise forward stepwise
regression. The middle panel shows the extents of transcribed regions of genes (horizontal lines)
and exons (vertical lines). The lower panel shows recombination rate estimates from the 1000
genomes reference panel in centiMorgan/mega base pair units.
6.4 Untargeted UPLC-MS metabolomic analysis of serum could
not reliably separate PC patients from controls
In paper IV, we performed a “metabolome-wide association study” in PC. The GWAS
approach of screening an entire class of similar variants for association with disease or other
traits was applied to the serum metabolome of PC patients and population controls.
Serum samples from 188 control subjects, 188 PC cases with indolent disease, and 99
PC cases with aggressive disease were selected from the CAPS biobank, and analyzed by
UPLC-MS by collaborators at Colorado State University, Fort Collins, CO, USA. The UPLC-
MS data were then postprocessed and transformed into quantitative measurements of 6,138
metabolite “features”.
Each feature corresponds to an intensity peak in the UPLC-MS chromatograms, which in
turn correspond to a detected ion or ion fragment from the analyzed sample, or in some cases
to noise. A single molecule species in the serum sample may correspond to several correlated
peaks in the output due to fragmentation and the creation of adduct ions in the UPLC-MS
process, and variations in isotope composition of the source molecule species.
In an exploratory analysis, intensities of many of the features were found to be associated
with the age of the individual who had donated the serum sample. Furthermore, a significant
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portion of the feature intensities were associated with the length of time a serum sample had
spent in frozen storage before analysis (range approximately 6–9 years). Since both these
factors were also associated with disease status, they were adjusted for in the full regression
analysis.
Feature–PC association was assessed using linear regression and the ANOVA F-test,
testing whether each feature’s intensity differed significantly between the three PC status
categories, adjusted for sample storage time and age.
Two features were significantly associated with PC status after Bonferroni correction for
multiple testing (P-values 4.0 × 10−6 and 7.1 × 10−6 ). However, none of them could be
identified as a specific molecule.
We further examined whether pairwise differences between feature intensities (correspond-
ing to ratios between features as originally measured due to log-transformation of data)
showed stronger association to disease status than single features. The rationale for this was
that pairwise comparisons could potentially capture relations such as substrate–product in
biochemical pathways. However, no such pairwise difference was significantly associated with
PC status when considering the increased multiple testing burden of all pairwise comparisons.
The strongest (but nonsignificantly associated) feature ratios contained molecules putatively
identified as caprolactam, L-phosphatidic acid, and the tripeptide Tyr-Lys-Thr.
Finally, the four features showing the strongest association with PC status (not necessarily
metabolome-wide significant) were tested for association with genotypes of ∼1.4 million SNPs
(genotyped and imputed) genome-wide. Traits were analyzed by linear regression of feature
intensities on minor allele counts of genotypes, with no covariates. All four features had their
most strongly associated markers in introns of genes. One feature (identifier 174.1 53) had
a genome-wide significant association to a variant in the gene IL13RA1, which encodes a
subunit of the interleukin 13 receptor, another subunit of which has been suggested as a drug
target for prostate cancer treatment.
In conclusion, despite interesting auxiliary findings, the main aim of this study was to
find novel biomarkers useful in assessing prostate cancer risk and aggressiveness. This aim
was not fulfilled. The search performed within the scope of this paper was however far
from exhaustive, and additional molecular detection strategies and samples may yet find PC
biomarkers in the serum metabolome.
34
7 Conclusions and future perspective
7.1 Implications and future research based on the papers
Paper I Our multistage study provides strong evidence for association of rare MAGI1
CNVs with disease, and the association seems even more plausible given the many interaction
partners to MAGI1 that have been implied in psychiatric genetic epidemiology, and its role
in the synapse (detailed in paper I with supplemental information). However, the rarity of
these specific mutations may limit the utility of this knowledge. In future studies, common
variation in the region could be reexamined, with the prior suspicion of involvement with
BPAD and SZ lowering the required significance threshold compared to that required for a
“hypothesis-free” GWAS.
Should the common variant approach not yield positive results, an alternative would
be to perform deep resequencing of the MAGI1 region in pedigrees with a high BPAD
and/or SZ load, or even in unrelated cases and control subjects. Using the “next-generation”
high-throughput sequencing technologies which have become available and affordable over
the past few years, large numbers of subjects could be sequenced affordably. If MAGI1 is
important in BPAD and SZ pathways, there should be other rare variants than large CNVs
affecting the gene’s function in large cohorts of cases. A large scale resequencing study would
clarify this.
A final intriguing lane of research would be to try and locate relatives of unrelated MAGI1
CNV carriers, in order to increase understanding of the penetrance of these variants. If
MAGI1 CNVs are confirmed as highly penetrant susceptibility variants they would provide
valuable markers for genetic counseling in families highly affected by BPAD and SZ.
Paper II We have shown that carriers of the HOXB13 G84E mutation are at considerable
increased risk of developing PC, with one out of three carriers being affected during their
lifetime. Our results agree with other replication studies in different populations, confirming
the G84E mutation as strongly associated with prostate cancer [87, 88, 89, 90]. A fundamental
difference in the Swedish population investigated herein is the relatively high prevalence
of the mutation in control subjects (1.4%) as compared to other populations. In general,
the mutation has been observed to be very rare in control populations outside the Nordic
countries, supporting the hypothesis that G84E is a founder mutation of Nordic origin. This
is further supported by our haplotype analysis, in which a single unique 108 kb haplotype
carried the G84E risk allele in the Swedish population. Finally, a Chinese case-control study of
HOXB13 variants in PC found no carriers of G84E [91], and the International Consortium for
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Prostate Cancer Genetics noted that none of their investigated families of African, Ashkenazi
Jewish, or “Other” descent (excluding European) had any carriers of the variant [89].
To further explore the risk predictive capacity of G84E we stratified mutation carriers by a
polygenic risk score composed of thirty-three established low-penetrant susceptibility variants.
Mutation carriers in the top quartile of the risk score were at considerably elevated risk of
PC with an estimated lifetime risk of 48%. Thus, integrating established PC susceptibility
variants in risk prediction models may make targeted screening and intervention programs
feasible, and additional efforts to translate PC genetic risk prediction into the clinical setting
are highly warranted.
The identification of the HOXB13 G84E mutation suggests the existence of other rare,
moderately penetrant, susceptibility variants in PC genetics. Therefore, additional studies
designed to identify such rare variants are highly warranted. Next-generation sequencing
assessment of linked genomic regions for hereditary PC cases may provide an effective approach
to identify additional rare variants.
Looking back to paper I, the findings of both studies indicate that new technologies such
as CNV detection and deep resequencing applied to linkage regions from previously collected
family materials can lead to new discoveries. The former study exemplifies the approach
using CNVs and family-wise linkage, and the HOXB13 G84E variant studied in paper II was
first discovered by resequencing of genes in the 17q21-22 linkage region in PC families [58].
Paper III We have provided independent replication of previous GWAS findings for TGCT
in a large, Scandinavian, case-parent, case-control sample. In addition to the straightforward
replication, we also found indications of the effect of variants in the gene SPRY4 on TGCT
risk being modified by parental sex – the identity of the transmitted allele only made a
difference for disease risk when inherited from mothers of cases. The mechanism behind this
phenomenon is not clear. An interesting future study would be to assess genomic inactivation
by methylation in the region where the parent-of-origin effect was detected, in cases as well
as in their parents.
As for any other complex disease, there are most likely more risk loci of smaller effect
waiting to be uncovered for TGCT. Considering that TGCT is the least common of the
diseases investigated in this thesis, international collaborations may be required to find these
variants. As a first step towards participation in an international meta-analysis, the cases
and case-parent constellations analyzed in paper III should be genotyped on a genome-wide
SNP chip, and a GWAS be performed.
Finally, the SNPs found to be associated with TGCT in paper III and in the GWASs
motivating the study may not be the actual variants that cause the increase in disease risk,
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but only correlate with causal variants through LD. By resequencing the association regions
in a subset of cases and controls, we may find variants of even stronger effect, which are
actually causative of TGCT.
Paper IV We examined the UPLC-MS-detectable human serum metabolome for molecules
associated with PC status, with the primary aim of finding molecules useful as biomarkers for
PC aggressiveness. We were also interested in searching for any molecules that differed signif-
icantly in abundance in serum from PC cases compared to controls, even if not immediately
useful as biomarkers, in order to inform us about disease mechanisms.
Two metabolomic features were significantly associated with disease status, but none of
them could be unambiguously identified.
Future analyses could include analyzing the same samples by gas chromatography–mass
spectrometry (GC–MS), which partly detects another spectrum of molecules, and with
properties of the detection procedure making molecular identification of associated traits
easier.
One could also imagine multivariate data mining or machine learning methods having
better success in finding patterns separating cases from controls, than the simple regres-
sion models applied in paper IV. However, with more complex models come difficulties in
interpreting their parameters, and in achieving independent replication.
The metabolome is a dynamic entity, constantly responding to environmental influ-
ences [92]. Compared to the relative stability of genomic DNA, there is thus much time-varying
noise inherent in metabolomic analyses, which may hinder inference.
7.2 Future perspective on molecular/genetic epidemiology research
Assuming we knew the full genomic DNA sequence of everyone, which research questions could
we answer? The somewhat unfortunately named “next generation” sequencing technologies
(what should we call the next next generation?) have in just a few years delivered vast
amounts of individual sequence data. In 2007 and 2008 the first personal genomes of James
Watson [93], Craig Venter [94], and an anonymous Han Chinese donor [95] were presented
as major scientific milestones, and the 1,000 genomes project (1kG) was initiated and
announced its intent to sequence and make available for research at least one thousand human
genomes [96]. Today, only four years later, the 1kG project has delivered the promised dense
map of human genetic variation [97], and many personal genomes have been sequenced in
clinical and research settings. Although the cost for sequencing a personal genome has not
yet plummeted to the 1,000 (US) dollar genome, it seems to be on its way there.
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In a clinical personal genomic era we will undoubtedly find unexpected disease-associated
variation in almost everyone. If whole genome sequencing is to become routine as part of
a screening program, we need a much greater understanding of which variants are actually
harmful (e.g. BRCA1 mutations in breast cancer), and which are not (e.g. any of a large
number of theoretically deleterious but in practice neutral variants discovered through whole
genome sequencing [98]). Furthermore, if no action can be taken on a discovered allele
increasing risk for a disease, would the (prospective) patient want to know that he or she
carries it? In these still early days, genomic sequence will probably be of greater use in
the research laboratory than in the clinic. There, molecular mechanisms of disease can be
elucidated, and treatment strategies based on these mechanisms can be devised.
38
8 Acknowledgements
Many people have been involved and invaluable in my journey from registration to dissertation,
and I hope I have not forgotten too many of you. My sincerest thanks to:
Fredrik Wiklund, my current main supervisor, who with incurable optimism and Norrlandish
realism has guided me through the second half of my thesis work.
Silvia Paddock, my former main supervisor, who picked me up from the mathematics
department, taught me all about human genetics, and got me on the Ph.D. train.
Juni Palmgren and Jonathan Prince, my co-supervisors. Juni impressed me from day one,
and through her immense connectedness and academic matchmaking skills I ended up at the
department of Medical Epidemiology and Biostatistics for the second half of my thesis work.
Jonathan, though no longer at the department, keeps inspiring from a distance.
Magnus Svedjebratt, my external mentor, always ready to provide good advice on request.
Fellow, former, and future friendly graduate students, biostatisticians, staff and faculty at
MEB, including but not limited to: Robert Szulkin, Caroline Weibull, Henrik Olsson, Emil
Rehnberg, Sandra Eloranta, Therese Andersson, Anna Johansson, Hatef Darabi, Mun-Gwan
Hong, Linda Abrahamsson, Iffat Rahman, Ralf Kuja-Halkola, Thomas Frisell, Lovisa Ho¨gberg,
Adina Feldman, Martin Fransson, Stephanie Bonn, Sara Christensen, Lisa Mo¨ller, Maria
Sandberg, Andrea Ganna, Johanna Holm, Karin Sundstro¨m, Amy Leva´l, Miriam Elfstro¨m,
Vilhelmina Ullemar, Ci Song, Markus Aly, Therese Ljung, Ma˚rten Neiman, Martin Eklund,
Anna Ka¨hler, Jitender Kumar, Mark Clements, Keith Humphreys, Yudi Pawitan, Marie
Reilly, Marie Jansson, Gunilla Sonnebring, Erika Nordenhagen, Sven Sandin, Alex Ploner,
Arvid Sjo¨lander, Cecilia Lundholm, Paul Dickman, Patrik Magnusson, Kamila Czene. Thank
you for good company and inspiration along the way!
Henrik Gro¨nberg, head of the department of Medical Epidemiology and Biostatistics.
Friends and faculty from the department of Neuroscience: Lisette Graae, Magnus Lekman,
Caroline Ran, Anna Anvret, Mimi Westerlund, Andrea Carmine Belin, Dagmar Galter,
Mathew Abrams, Susanne Szydlowski, Sophia Savage, Lars Olson, Karin Pernold, Karin
Lundstro¨mer, Eva Lindqvist. Thank YOU for good company along the way!
Ida Engqvist, IT coordinator at the department of Neuroscience, and a source of endless IT
wisdom and wizardry.
39
The KIRC group: Helga Westerlind, Ryan Ramanujam, Henrik Ka¨llberg, Johan Acevedo,
Boel Brynedal, Daniel Uvehag, Jonas Forsslund. Keep KI nerdy!
Ulf Rydmark who taught me mathematics, och Per Cederholm som la¨rde mig ord.
The MEB IT group, who always keep the servers humming. Special thanks to resident Linux
gurus Zack Yusuf and Rikard O¨berg.
Collaborators in Norway: Tom Grotmol, Trine Haugen, Wenche Kristiansen, Kristine An-
dreassen, Elin Aschim.
Family: Ulf Karlsson, Lena Malmstedt, Ellinor Larsson, Per Ekholm. Ga¨rd Allvin who always
kept me well fed, Karin and Yngve Allvin who always managed to seem interested in what
I’ve been doing.
Helen ♥ ∞
40
References
[1] Watson JD, Crick FHC. Molecular Structure of Nucleic Acids: A Structure for Deoxyri-
bose Nucleic Acid. Nature. 1953;171(4356):737–738.
[2] Watson JD, Crick FHC. Genetical Implications of the Structure of Deoxyribonucleic
Acid. Nature. 1953;171(4361):964–967.
[3] Crick F. Central dogma of molecular biology. Nature. 1970;227(5258):561–563.
[4] Bird AP. CpG-rich islands and the function of DNA methylation. Nature.
1986;321(6067):209–213.
[5] Hannon GJ. RNA interference. Nature. 2002;418(6894):244–251.
[6] Nagano T, Fraser P. No-Nonsense Functions for Long Noncoding RNAs. Cell.
2011;145(2):178–181.
[7] Huarte M, Rinn JL. Large non-coding RNAs: missing links in cancer? Human Molecular
Genetics. 2010;19(R2):R152–R161.
[8] Mendel GV. Versuche U¨ber Pflanzen-Hybriden. Journal of Heredity. 1951;42(1):3–4.
[9] Wiener AS. Method of Measuring Linkage in Human Genetics; with Special Reference
to Blood Groups. Genetics. 1932;17(3):335–350.
[10] Ott J. Analysis of Human Genetic Linkage. Johns Hopkins University Press; 1999.
[11] Kruglyak L. The use of a genetic map of biallelic markers in linkage studies. Nature
Genetics. 1997;17(1):21–24.
[12] Sherry ST, Ward MH, Kholodov M, Baker J, Phan L, Smigielski EM, et al. dbSNP: the
NCBI database of genetic variation. Nucleic Acids Research. 2001;29(1):308–311.
[13] Sebat J, Lakshmi B, Troge J, Alexander J, Young J, Lundin P, et al. Large-Scale Copy
Number Polymorphism in the Human Genome. Science. 2004;305(5683):525–528.
[14] Risch N, Merikangas K. The Future of Genetic Studies of Complex Human Diseases.
Science. 1996;273(5281):1516–1517.
[15] Klein RJ, Zeiss C, Chew EY, Tsai JY, Sackler RS, Haynes C, et al. Complement Factor H
Polymorphism in Age-Related Macular Degeneration. Science. 2005;308(5720):385–389.
41
[16] The Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000
cases of seven common diseases and 3,000 shared controls. Nature. 2007;447(7145):661–
678.
[17] Visscher PM, Brown MA, McCarthy MI, Yang J. Five Years of GWAS Discovery.
American Journal of Human Genetics. 2012;90(1):7–24.
[18] National Human Genome Research Institute. Talking Glossary of Genetic Terms. National
Institutes of Health;. Available from: http://www.genome.gov/glossary/?id=114.
[19] Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, et al. Initial
sequencing and analysis of the human genome. Nature. 2001;409(6822):860–921.
[20] Venter JC, Adams MD, Myers EW, Li PW, Mural RJ, Sutton GG, et al. The Sequence
of the Human Genome. Science. 2001;291(5507):1304–1351.
[21] Rice TK, Borecki IB. Familial resemblance and heritability. In: Advances in Genetics.
vol. Volume 42. Academic Press; 2001. p. 35–44.
[22] Maher B. Personal genomes: The case of the missing heritability. Nature News.
2008;456(7218):18–21.
[23] Manolio TA, Collins FS, Cox NJ, Goldstein DB, Hindorff LA, Hunter DJ, et al. Finding
the missing heritability of complex diseases. Nature. 2009;461(7265):747–753.
[24] Zuk O, Hechter E, Sunyaev SR, Lander ES. The mystery of missing heritability: Genetic
interactions create phantom heritability. Proceedings of the National Academy of Sciences.
2012;109(4):1193–1198.
[25] Hardy GH. Mendelian Proportions in a Mixed Population. Science. 1908;28(706):49–50.
[26] American Psychiatric Association. Diagnostic and statistical manual of mental disorders:
DSM-IV. American Psychiatric Association; 1994.
[27] Lichtenstein P, Yip BH, Bjo¨rk C, Pawitan Y, Cannon TD, Sullivan PF, et al. Com-
mon genetic determinants of schizophrenia and bipolar disorder in Swedish families: a
population-based study. Lancet. 2009;373(9659):234–239.
[28] The International Schizophrenia Consortium. Common polygenic variation contributes
to risk of schizophrenia and bipolar disorder. Nature. 2009;460(7256):748–752.
[29] Craddock N, Owen MJ. The Kraepelinian dichotomy - going, going... but still not gone.
The British Journal of Psychiatry. 2010;196(2):92–95.
42
[30] McGrath J, Saha S, Chant D, Welham J. Schizophrenia: A Concise Overview of
Incidence, Prevalence, and Mortality. Epidemiologic Reviews. 2008;30(1):67–76.
[31] Merikangas KR, Jin R, He JP, Kessler RC, Lee S, Sampson NA, et al. Prevalence and
correlates of bipolar spectrum disorder in the world mental health survey initiative.
Archives of general psychiatry. 2011;68(3):241–251.
[32] Osby U, Brandt L, Correia N, Ekbom A, Spare´n P. Excess mortality in bipolar and
unipolar disorder in Sweden. Archives of general psychiatry. 2001;58(9):844–850.
[33] McGrath JJ. Variations in the Incidence of Schizophrenia: Data Versus Dogma.
Schizophrenia Bulletin. 2006;32(1):195–197.
[34] Tsuchiya KJ, Byrne M, Mortensen PB. Risk factors in relation to an emergence of
bipolar disorder: a systematic review. Bipolar Disorders. 2003;5(4):231–242.
[35] Frans EM, Sandin S, Reichenberg A, Lichtenstein P, L˚angstro¨m N, Hultman CM. Advanc-
ing paternal age and bipolar disorder. Archives of general psychiatry. 2008;65(9):1034–
1040.
[36] Sullivan PF, Daly MJ, O’Donovan M. Genetic architectures of psychiatric disorders: the
emerging picture and its implications. Nature Reviews Genetics. 2012;13(8):537–551.
[37] Millar JK, Wilson-Annan JC, Anderson S, Christie S, Taylor MS, Semple CAM, et al.
Disruption of two novel genes by a translocation co-segregating with schizophrenia.
Human Molecular Genetics. 2000;9(9):1415–1423.
[38] Sanders M, Duan P, Levinson M, Shi P, He B, Hou B, et al. No Significant Association
of 14 Candidate Genes With Schizophrenia in a Large European Ancestry Sample:
Implications for Psychiatric Genetics. American Journal of Psychiatry. 2008;165(4):497–
506.
[39] Kim Y, Zerwas S, Trace SE, Sullivan PF. Schizophrenia Genetics: Where Next?
Schizophrenia Bulletin. 2011;37(3):456–463.
[40] The International Schizophrenia Consortium. Rare chromosomal deletions and duplica-
tions increase risk of schizophrenia. Nature. 2008;455(7210):237–241.
[41] The Schizophrenia Psychiatric Genome-Wide Association Study (GWAS) Consortium.
Genome-wide association study identifies five new schizophrenia loci. Nat Genet.
2011;43(10):969–976.
43
[42] Sklar P, Smoller J, Fan J, Ferreira M, Perlis R, Chambert K, et al. Whole-genome
association study of bipolar disorder. Molecular Psychiatry. 2008;13(6):558–569.
[43] Psychiatric GWAS Consortium Bipolar Disorder Working Group. Large-scale genome-
wide association analysis of bipolar disorder identifies a new susceptibility locus near
ODZ4. Nature Genetics. 2011;43(10):977–983.
[44] Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics.
CA: A Cancer Journal for Clinicians. 2011;61(2):69–90.
[45] Engholm G, Ferlay J, Christensen N, Bray F, Gjerstorff ML, Klint A˚, et al. NORDCAN
– a Nordic tool for cancer information, planning, quality control and research. Acta
Oncologica. 2010;49(5):725–736.
[46] Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-Specific
Antigen as a Serum Marker for Adenocarcinoma of the Prostate. New England Journal
of Medicine. 1987;317(15):909–916.
[47] Welch HG, Black WC. Overdiagnosis in Cancer. Journal of the National Cancer Institute.
2010;102(9):605–613.
[48] Nordstro¨m T, Aly M, Clements MS, Weibull CE, Adolfsson J, Gro¨nberg H.
Prostate-specific Antigen (PSA) Testing Is Prevalent and Increasing in Stockholm
County, Sweden, Despite No Recommendations for PSA Screening: Results from
a Population-based Study, 2003–2011. European Urology. 2012;[Epub ahead of
print]:http://dx.doi.org/10.1016/j.eururo.2012.10.001.
[49] Schro¨der FH, Hugosson J, Roobol MJ, Tammela TLJ, Ciatto S, Nelen V, et al. Prostate-
cancer mortality at 11 years of follow-up. The New England journal of medicine.
2012;366(11):981–990.
[50] Andriole GL, Crawford ED, Grubb RL, Buys SS, Chia D, Church TR, et al. Prostate
Cancer Screening in the Randomized Prostate, Lung, Colorectal, and Ovarian Cancer
Screening Trial: Mortality Results after 13 Years of Follow-up. Journal of the National
Cancer Institute. 2012;104(2):125–132.
[51] Gro¨nberg H. Prostate cancer epidemiology. The Lancet. 2003;361(9360):859–864.
[52] Venkateswaran V, Klotz LH. Diet and prostate cancer: mechanisms of action and
implications for chemoprevention. Nature Reviews Urology. 2010;7(8):442–453.
44
[53] Hedelin M, Chang ET, Wiklund F, Bellocco R, Klint A˚, Adolfsson J, et al. Association
of frequent consumption of fatty fish with prostate cancer risk is modified by COX-2
polymorphism. International Journal of Cancer. 2007;120(2):398–405.
[54] Hedelin M, Klint A˚, Chang E, Bellocco R, Johansson JE, Andersson SO, et al. Dietary
Phytoestrogen, Serum Enterolactone and Risk of Prostate Cancer: The Cancer Prostate
Sweden Study (Sweden). Cancer Causes and Control. 2006;17(2):169–180.
[55] Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M, et al.
Environmental and Heritable Factors in the Causation of Cancer — Analyses of Cohorts
of Twins from Sweden, Denmark, and Finland. New England Journal of Medicine.
2000;343(2):78–85.
[56] Sundararajan S, Ahmed A, Goodman J Oscar B. The relevance of BRCA genetics
to prostate cancer pathogenesis and treatment. Clinical Advances in Hematology &
Oncology: H&O. 2011;9(10):748–755.
[57] Goh CL, Schumacher FR, Easton D, Muir K, Henderson B, Kote-Jarai Z, et al. Ge-
netic variants associated with predisposition to prostate cancer and potential clinical
implications. Journal of Internal Medicine. 2012;271(4):353–365.
[58] Ewing CM, Ray AM, Lange EM, Zuhlke KA, Robbins CM, Tembe WD, et al. Germline
Mutations in HOXB13 and Prostate-Cancer Risk. New England Journal of Medicine.
2012;366(2):141–149.
[59] Bosl GJ, Motzer RJ. Testicular Germ-Cell Cancer. New England Journal of Medicine.
1997;337(4):242–254.
[60] Rosen A, Jayram G, Drazer M, Eggener SE. Global Trends in Testicular Cancer Incidence
and Mortality. European Urology. 2011;60(2):374–379.
[61] Hemminki K, Li X. Familial risk in testicular cancer as a clue to a heritable and
environmental aetiology. British Journal of Cancer. 2004;90(9):1765–1770.
[62] Peng X, Zeng X, Peng S, Deng D, Zhang J. The Association Risk of Male Subfertility
and Testicular Cancer: A Systematic Review. PLoS ONE. 2009;4(5):e5591.
[63] Czene K, Lichtenstein P, Hemminki K. Environmental and heritable causes of cancer
among 9.6 million individuals in the Swedish family-cancer database. International
Journal of Cancer. 2002;99(2):260–266.
45
[64] Nathanson KL, Kanetsky PA, Hawes R, Vaughn DJ, Letrero R, Tucker K, et al. The Y
Deletion gr/gr and Susceptibility to Testicular Germ Cell Tumor. The American Journal
of Human Genetics. 2005;77(6):1034–1043.
[65] Rapley EA, Turnbull C, Al Olama AA, Dermitzakis ET, Linger R, Huddart RA,
et al. A genome-wide association study of testicular germ cell tumor. Nature Ge-
netics. 2009;41(7):807–810.
[66] Kanetsky PA, Mitra N, Vardhanabhuti S, Vaughn DJ, Li M, Ciosek SL, et al. A Second
Independent Locus Within DMRT1 Is Associated with Testicular Germ Cell Tumor
Susceptibility. Human Molecular Genetics. 2011;20(15):3109–3117.
[67] Kanetsky PA, Mitra N, Vardhanabhuti S, Li M, Vaughn DJ, Letrero R, et al. Common
variation in KITLG and at 5q31.3 predisposes to testicular germ cell cancer. Nature
Genetics. 2009;41(7):811–815.
[68] Turnbull C, Rapley EA, Seal S, Pernet D, Renwick A, Hughes D, et al. Variants near
DMRT1, TERT and ATF7IP are associated with testicular germ cell cancer. Nature
Genetics. 2010;42(7):604–607.
[69] Chung C, Wang Z, Kanetsky P, Turnbull C, McGlynn K, Erickson R, et al. Meta-analysis
identifies four new loci for testicular germ cell tumor. In: the 62nd Annual Meeting of
The American Society of Human Genetics. San Francisco, CA, USA; 2012. p. #213.
[70] The National Institute of Mental Health. NIMH Bipolar Disorder Genetics Initiative;
[Accessed 13th December 2012]. [Online]. Available from: http://www.nimhgenetics.
org/available_data/bipolar_disorder/.
[71] Olama AAA, Kote-Jarai Z, Schumacher FR, Wiklund F, Berndt SI, Benlloch S, et al. A
meta-analysis of genome-wide association studies to identify prostate cancer susceptibility
loci associated with aggressive and non-aggressive disease. Human Molecular Genetics.
2012;[Epub ahead of print]:http://dx.doi.org/10.1093/hmg/dds425.
[72] Schumacher FR, Berndt SI, Siddiq A, Jacobs KB, Wang Z, Lindstrom S, et al. Genome-
wide association study identifies new prostate cancer susceptibility loci. Human Molecular
Genetics. 2011;20(19):3867–3875.
[73] Aly M, Wiklund F, Xu J, Isaacs WB, Eklund M, D’Amato M, et al. Polygenic Risk
Score Improves Prostate Cancer Risk Prediction: Results from the Stockholm-1 Cohort
Study. European Urology. 2011;60(1):21–28.
46
[74] Kristiansen W, Andreassen KE, Karlsson R, Aschim EL, Bremnes RM, Dahl O, et al.
Gene Variations in Sex Hormone Pathways and the Risk of Testicular Germ Cell Tumour:
A Case–Parent Triad Study in a Norwegian–Swedish Population. Human Reproduction.
2012;27(5):1525–1535.
[75] Rahman I, Bennet AM, Pedersen NL, de Faire U, Svensson P, Magnusson PKE. Genetic
Dominance Influences Blood Biomarker Levels in a Sample of 12,000 Swedish Elderly
Twins. Twin Research and Human Genetics. 2009;12(03):286–294.
[76] Ragoussis J. Genotyping Technologies for Genetic Research. Annual Review of Genomics
and Human Genetics. 2009;10(1):117–133.
[77] Kong A, Cox NJ. Allele-Sharing Models: LOD Scores and Accurate Linkage Tests. The
American Journal of Human Genetics. 1997;61(5):1179–1188.
[78] Wang K, Li M, Hadley D, Liu R, Glessner J, Grant SF, et al. PennCNV: An integrated
hidden Markov model designed for high-resolution copy number variation detection in
whole-genome SNP genotyping data. Genome Research. 2007;17(11):1665–1674.
[79] Anderson CA, Pettersson FH, Clarke GM, Cardon LR, Morris AP, Zondervan KT.
Data quality control in genetic case-control association studies. Nature Protocols.
2010;5(9):1564–1573.
[80] Lambert CG, Black LJ. Learning from our GWAS mistakes: from experimental design
to scientific method. Biostatistics. 2012;13(2):195–203.
[81] Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MAR, Bender D, et al. PLINK:
a tool set for whole-genome association and population-based linkage analyses. American
Journal of Human Genetics. 2007;81(3):559–75.
[82] R Development Core Team. R: A Language and Environment for Statistical Computing.
Vienna, Austria: R Foundation for Statistical Computing; 2012.
[83] Browning BL, Browning SR. A Unified Approach to Genotype Imputation and Haplotype-
Phase Inference for Large Data Sets of Trios and Unrelated Individuals. The American
Journal of Human Genetics. 2009;84(2):210–223.
[84] Browning SR, Browning BL. Rapid and Accurate Haplotype Phasing and Missing-
Data Inference for Whole-Genome Association Studies By Use of Localized Haplotype
Clustering. The American Journal of Human Genetics. 2007;81(5):1084–1097.
47
[85] Dudbridge F. Likelihood-Based Association Analysis for Nuclear Families and Unrelated
Subjects with Missing Genotype Data. Human heredity. 2008;66(2):87–98.
[86] Smith CA, Want EJ, O’Maille G, Abagyan R, Siuzdak G. XCMS: Processing Mass
Spectrometry Data for Metabolite Profiling Using Nonlinear Peak Alignment, Matching,
and Identification. Analytical Chemistry. 2006;78(3):779–787.
[87] Akbari MR, Trachtenberg J, Lee J, Tam S, Bristow R, Loblaw A, et al. Association
Between Germline HOXB13 G84E Mutation and Risk of Prostate Cancer. Journal of
the National Cancer Institute. 2012;104(16):1260–1262.
[88] Breyer JP, Avritt TG, McReynolds KM, Dupont WD, Smith JR. Confirmation of the
HOXB13 G84E Germline Mutation in Familial Prostate Cancer. Cancer Epidemiology
Biomarkers & Prevention. 2012;21(8):1348–1353.
[89] Xu J, Lange E, Lu L, Zheng S, Wang Z, Thibodeau S, et al. HOXB13 is a
susceptibility gene for prostate cancer: results from the International Consortium
for Prostate Cancer Genetics (ICPCG). Human Genetics. 2012;[Epub ahead of
print]:http://dx.doi.org/10.1007/s00439–012–1229–4.
[90] Stott-Miller M, Karyadi DM, Smith T, Kwon EM, Kolb S, Stanford JL, et al. HOXB13
mutations in a population-based, case–control study of prostate cancer. The Prostate.
2012;[Epub ahead of print]:http://dx.doi.org/10.1002/pros.22604.
[91] Lin X, Qu L, Chen Z, Xu C, Ye D, Shao Q, et al. A novel Germline mutation in HOXB13
is associated with prostate cancer risk in Chinese men. The Prostate. 2012;[Epub ahead
of print]:http://dx.doi.org/10.1002/pros.22552.
[92] Krug S, Kastenmuller G, Stu¨ckler F, Rist MJ, Skurk T, Sailer M, et al. The dynamic range
of the human metabolome revealed by challenges. The FASEB Journal. 2012;26(6):2607–
2619.
[93] Wheeler DA, Srinivasan M, Egholm M, Shen Y, Chen L, McGuire A, et al. The
complete genome of an individual by massively parallel DNA sequencing. Nature.
2008;452(7189):872–876.
[94] Levy S, Sutton G, Ng PC, Feuk L, Halpern AL, Walenz BP, et al. The Diploid Genome
Sequence of an Individual Human. PLoS Biol. 2007;5(10):e254.
[95] Wang J, Wang W, Li R, Li Y, Tian G, Goodman L, et al. The diploid genome sequence
of an Asian individual. Nature. 2008;456(7218):60–65.
48
[96] The 1000 Genomes Project. International Consortium Announces the 1000 Genomes
Project; 2008. Press Release. Available from: http://www.1000genomes.org/sites/
1000genomes.org/files/docs/1000genomes-newsrelease.pdf.
[97] The 1000 Genomes Project Consortium. An integrated map of genetic variation from
1,092 human genomes. Nature. 2012;491(7422):56–65.
[98] Xue Y, Chen Y, Ayub Q, Huang N, Ball EV, Mort M, et al. Deleterious- and Disease-
Allele Prevalence in Healthy Individuals: Insights from Current Predictions, Mutation
Databases, and Population-Scale Resequencing. The American Journal of Human
Genetics. 2012;91(6):1022–1032.
49
